Skip To Main Content
Maddalena Barba on Muck Rack

Maddalena Barba

As seen in: Nature, Memory Studies, International Journal of Medical Sciences
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Maddalena

Contact Maddalena, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Platinum-based neoadjuvant chemotherapy and the predictive role of DNA damage response biomarkers in TNBC: the NeoCarbo study

|
By Eriseld Krasniqi, Anna Di Benedetto, Lorena Filomeno, Teresa Arcuri, Cristiana Ercolani, Gianluigi Ferretti, Simona Gasparro, Laura Pizzuti, Maddalena Barba, Claudio Botti, Franco Graziano, Ida Paris, Fabio Calabrò, Sandra Rea, Roy de Vita, Giuseppe Sanguineti, Silvia Takanen, Laura Greco, Marco Mazzotta, Nicola Calonaci, Mauro Minelli, Giulio Caravagna, Giovanni Blandino, Patrizia Vici, Alberto Fulvi, Arianna Roselli, Loretta D’Onofrio, Marcello Maugeri-Saccà, Ilaria Puccica, Sonia Cappelli, Fabio Pelle, Flavia Cavicchi, Amedeo Villanucci, Tatiana D’Angelo, Letizia Perracchio, Laura Marucci, Lucia Goanta, Ramy Kayal, Pina Tiziana Falbo, Paola Scavina, Matteo Vergati, Giuliana D’Auria
| Nature Verified
Abstract Platinum-containing neoadjuvant chemotherapy increases pathological complete response (pCR) rates in triple-negative breast cancer (TNBC), but predictive biomarkers remain incompletely defined. In the multicenter NeoCarbo cohort, we assessed a carboplatin-containing neoadjuvant regimen and examined whether germline homologous recombination deficiency (HRD) and baseline tumor DNA damage response (DDR) activation predict pCR and outcomes.
Open in Who Shared Issue with article?

PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting - Laura Pizzuti, Eriseld Krasniqi, Isabella Sperduti, Maddalena Barba, Teresa Gamucci, M

|
By Laura Pizzuti, Eriseld Krasniqi, Isabella Sperduti, Maddalena Barba
| Memory Studies
Introduction The overexpression of the human epidermal growth factor receptor-2 (HER2) and inherent gene amplification is reported in 15–20% of breast cancers (BCs).
Open in Who Shared Issue with article?

Burnout of health care providers during the COVID-19 pandemic: Focus on Medical Oncologists

|
By Patrizia Vici, Eriseld Krasniqi, Laura Pizzuti, Gennaro Ciliberto, Marco Mazzotta, Daniele Marinelli, Maddalena Barba
| International Journal of Medical Sciences Verified
Int J Med Sci 2021; 18(10):2235-2238. doi:10.7150/ijms.54025 Letter Patrizia Vici1, Eriseld Krasniqi1, Laura Pizzuti1, Gennaro Ciliberto2, Marco Mazzotta1, , Daniele Marinelli3, Maddalena Barba1, 1. Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi, 00144 Rome, Italy 2. Scientific Direction, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy 3.
Open in Who Shared Issue with article?
See all 3 articles